|
1.
|
Fujii J and Ikeda Y: Advances in our
understanding of peroxiredoxin, a multifunctional, mammalian redox
protein. Redox Rep. 7:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Hofmann B, Hecht HJ and Flohe L:
Peroxiredoxins. Biol Chem. 383:347–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Wood ZA, Schröder E, Harris JR and Poole
LB: Structure, mechanism and regulation of peroxiredoxins. Trends
Biochem Sci. 28:32–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Immenschuh S and Baumgart-Vogt E:
Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid
Redox Signal. 7:768–777. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Rhee SG, Chae HZ and Kim K:
Peroxiredoxins: A historical overview and speculative preview of
novel mechanisms and emerging concepts in cell signaling. Free Rad
Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Halliwell B and Gutteridge J: Free
Radicals in Biology and Medicine. 3rd edition. Oxford University
Press; New York, NY: 1999
|
|
7.
|
Halliwell B: Oxidative stress and cancer:
have we moved forward? Biochem J. 401:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Valko M, Rhodes CJ, Moncol J, Izakovic M
and Mazur M: Free radicals, metals and antioxidants in oxidative
stress-induced cancer. Chem Biol Interact. 160:1–40. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Butterfield LH, Merino A, Golub SH and
Shau H: From cytoprotection to tumor suppression: the
multifactorial role of peroxiredoxins. Antioxid Redox Signal.
1:385–402. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA
and Chae HZ: Overexpression of peroxiredoxin in human breast
cancer. Anticancer Res. 21:2085–2090. 2001.
|
|
11.
|
Kinnula VL, Lehtonen S, Sormunen R,
Kaarteenaho-Wiik R, Kang SW, Rhee SG and Soini Y: Overexpression of
peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J
Pathol. 196:316–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Karihtala P, Mantyniemi A, Kang SW,
Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin
Cancer Res. 15:3418–3424. 2003.
|
|
13.
|
Lehtonen ST, Svensk AM, Soini Y, Paakko P,
Hirvikoski P, Kang SW and Saily M: Peroxiredoxins, a novel protein
family in lung cancer. Int J Cancer. 111:514–521. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Quan C, Cha EJ, Lee HL, Han KH, Lee KM and
Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates
with development recurrence and progression of human bladder
cancer. J Urolol. 175:1512–1516. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kinnula VL, Paakko P and Soini Y:
Antioxidant enzymes and redox regulating thiol proteins in
malignancies of human lung. FEBS Lett. 569:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Li DQ, Wang L, Fei F, Hou YF, Luo JM,
Wei-Chen, Zeng R, Wu J, Lu JS, Di GH, Ou ZL and Xia QC:
Identification of breast cancer metastasis-associated proteins in
an isogenic tumor metastasis model using two-dimensional gel
electrophoresis and liquid chromatography-ion trap-mass
spectrometry. Proteomics. 6:3352–3368. 2006. View Article : Google Scholar
|
|
17.
|
Neumann CA and Fang Q: Are peroxiredoxins
tumor suppressors? Curr Opin Pharm. 7:375–380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di
GH, Jin W, Ou ZL and Shen ZZ: Identification of the functional role
of peroxiredoxin 6 in the progression of breast cancer. Breast
Cancer Res. 9:R762007. View
Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ishii T, Warabi E and Yanagawa T: Novel
roles of peroxiredoxins in inflammation, cancer and innate
immunity. J Clin Biochem Nutr. 50:91–105. 2012.PubMed/NCBI
|
|
20.
|
Chahed K, Kabbage M, Hamrita B, Guillier
CL, Trimeche M, Remadi S, Ehret-Sabatier L and Chouchane L:
Detection of protein alterations in male breast cancer using two
dimensional gel electrophoresis and mass spectrometry: The
involvement of several pathways in tumorigenesis. Clin Chim Acta.
388:106–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Bae J, Ahn S, Han W and Noh D:
Peroxiredoxin I and II inhibit H2O2-induced
cell death in MCF-7 Cell Lines. J Cell Biochem. 101:1038–1045.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Goncalves K, Sullivan K and Phelan SA:
Differential expression and function of peroxiredoxin 1 and
peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast
epithelial cells. Cancer Invest. 30:38–47. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Tehan L, Taparra K and Phelan SA:
Peroxiredoxin overexpression in MCF-7 breast cancer cells and
regulation by cell proliferation and oxidative stress. Cancer
Invest. 31:374–384. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wang T, Tamae D, LeBon T, Shively JE, Yen
Y and Li JJ: The role of peroxiredoxin II in radiation-resistant
MCF-7 breast cancer cells. Cancer Res. 65:10338–10346. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hickman JA: Apoptosis induced by
anticancer drugs. Cancer Metastasis Rev. 11:121–139. 1992.
View Article : Google Scholar
|
|
27.
|
Osbild S, Brault L, Battaglia E and Bagrel
D: Resistance to cisplatin and adriamycin is associated with the
inhibition of glutathione efflux in MCF-7-derived cells. Anticancer
Res. 26:3595–3600. 2006.PubMed/NCBI
|
|
28.
|
Ishii T, Itoh K, Takahashi S, Sato H,
Yanagawa T, Katoh Y, Bannai S and Yamamoto M: Transcription factor
Nrf2 coordinately regulates a group of oxidative stress-inducible
genes in macrophages. J Biol Chem. 275:16023–16029. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Wonsey DR, Zeller KI and Dang CV: The
c-Myc target gene PRDX3 is required for mitochondrial homeostasis
and neoplastic transformation. Proc Natl Acad Sci USA.
99:6649–6654. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Li L, Zhang YG and Chen CL: Anti-apoptotic
role of peroxiredoxin III in cervical cancer cells. FEBS Open Bio.
3:51–54. 2012. View Article : Google Scholar
|
|
31.
|
Gajewski E, Gaur S, Akman SA, Matsumoto L,
van Balgooy JNA and Doroshowa JH: Oxidative DNA base damage in
MCF-10A breast epithelial cells at clinically achievable
concentrations of doxorubicin. Biochem Pharmacol. 73:1947–1956.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Diaz AJG, Tamae D, Yen Y, Li JJ and Wang
T: Enhanced radiation response in radioresistant MCF-7 cells by
targeting peroxiredoxin II. Breast Cancer (Dove Med Press).
5:87–101. 2013.PubMed/NCBI
|
|
33.
|
He T, Banach-Latapy A, Vernis L, Dardalhon
M, Chanet R and Huang ME: Peroxiredoxin 1 knockdown potentiates
β-lapachone cytotoxicity through modulation of reactive oxygen
species and mitogen-activated protein kinase signals.
Carcinogenesis. 34:760–769. 2013.
|
